Ofatumumab Shows Promise as a Multiple Sclerosis Treatment

11 July 2010 (Last Updated July 11th, 2010 18:30)

A Phase II study of ofatumumab has shown positive interim results for safety and pharmacokinetics in patients with relapsing-remitting multiple sclerosis (RRMS). Ofatumumab is a novel human monoclonal antibody to treat multiple sclerosis, and is being developed by Genmab in collaboration

A Phase II study of ofatumumab has shown positive interim results for safety and pharmacokinetics in patients with relapsing-remitting multiple sclerosis (RRMS).

Ofatumumab is a novel human monoclonal antibody to treat multiple sclerosis, and is being developed by Genmab in collaboration with GlaxoSmithKline.

The 48-week study randomised 38 patients with RRMS to evaluate the safety of three doses of ofatumumab and assess its efficacy.

The drug demonstrated statistically significant reductions in the number of brain lesions in all its dose groups compared to a placebo.